( and at least twice the incidence of ...)Data Suggest Cymbalta Improved Functioning in Patients with,Generalized Anxiety Disorder,Health

and at least twice the incidence of sugar pill) were: nausea; fatigue; dry mouth; somnolence; constipation; insomnia; appetite decreased; hyperhidrosis; libido decreased; vomiting; ejaculation delayed; and erectile dysfunction. Approximately 16 percent of patients taking Cymbalta discontinued treatment due to an adverse event compared to 4 percent of patients receiving sugar pill. The most common adverse events reported as reasons for discontinuation (occurring at a rate of less than or equal to 1.2 percent and at a significantly higher rate compared to sugar pill) were nausea, vomiting and dizziness.(3)

Methods

Data from two double-blind, placebo-controlled trials in adults with generalized anxiety disorder were pooled. In the first trial, patients received 60 mg of Cymbalta once daily, 120 mg once daily or sugar pill for nine weeks. In the second trial, patients were started at a dose of 60 mg of Cymbalta but dose could be increased to 120 mg once daily, or they were given sugar pill for 10 weeks.

In both trials, the Hamilton Anxiety Scale (HAMA) was used to measure anxious symptoms, the SDS was used to assess global functional impairment and the Visual Analog Scale for Overall Pain (VAS) was used to measure severity of painful physical symptoms. Pearson partial correlations were used to assess the magnitude and significance of the associations between global functional impairment and psychic anxiety or painful physical symptoms. Path analysis was used to assess the relative contributions of changes in psychic and somatic anxiety and painful physical symptoms on improved functional outcomes.

The large unexplained effect of Cymbalta implies that Cymbalta improves global functioning through the treatment of additional symptoms that the scales in our clinical trials do not measure. These symptoms could be related to other anxious symptoms, painful physical sym
'"/>

Page: 1 2 3 4 5 6
Related medicine technology :

1. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
2. Samaritans Alzheimers Drug Caprospinol Suggests Brain May be Able to Heal From Alzheimers Disease
3. Beike Biotechnology Study Suggests Adult Stem Cells Show Promise for Peripheral Vascular Disease
4. New Study in Journal of Pediatrics Suggests Synagis (Palivizumab) May Reduce Subsequent Recurrent Wheezing in Preterm Infants
5. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
6. Resveratrol Studies Suggest Broad Implications for SIRT1 Activation in Neurodegenerative Diseases of Aging Such as Alzheimers Disease
7. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
8. Three Studies Suggest Abbotts Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
9. New Study Suggests Better Patient Outcomes with CYPHER Sirolimus-Eluting Coronary Stent than with Taxus Stent in Real-World Clinical Settings
10. Study Suggests Strattera Improved ADHD Symptoms in Patients With Comorbid Alcohol Abuse
11. New Study Suggests no Significant Impairment in Middle-of-the-Night Balance, Mobility or Memory in Older Adults Using Ramelteon